Melanotan II for Health & Longevity - Quick Reference Sheet

Melanotan II for Health & Longevity

Created on 07/01/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

An injectable peptide that darkens skin without sun while raising sexual desire, triggering erections, and blunting appetite. These effects are real but the evidence is thin. Serious harms — changing moles and skin cancer, prolonged painful erections, raised blood pressure, and unregulated purity — weigh heavily against a mostly cosmetic reward. (Full Review)

Protocol

Regimen
Loading then maintenance
Small daily subcutaneous injections until desired tan develops, then one or two per week to sustain it
Titration
Start low, titrate slowly
Low test dose and gradual increase; smaller, more frequent doses favored over large single doses for tolerability
Timing
Evening injection
Common side effects (nausea, flushing, fatigue, spontaneous erection) are then less disruptive and can coincide with sleep
Time to effect
Tanning
1–3 weeks
Visible skin darkening with regular dosing
Sexual effects
1–3 hours
Onset after a single injection

Benefits

Contraindications
  • Personal or strong family history of melanoma, or many atypical moles
  • Uncontrolled hypertension (resting BP consistently >160/100 mmHg) or established cardiovascular/cerebrovascular disease
  • Prior priapism or sickle-cell disease
  • Pregnant or breastfeeding
  • Unable to ensure sterile injection technique and product quality
Key Interactions
  • PDE5 inhibitors (sildenafil, tadalafil)
  • OTC decongestants and stimulants with sympathomimetics (pseudoephedrine, phenylephrine)
  • Stimulant "fat burner" supplements (caffeine, synephrine, yohimbine)
  • Concurrent ultraviolet tanning (sunbeds, sun exposure)

Risk & Side Effects

  • High: Changing moles and melanoma concern; nausea and facial flushing
  • Medium: Priapism; cardiovascular and renal events
  • Low: Yawning, appetite loss, and fatigue
  • Speculative: Injection-site infections and blood-borne disease

Monitoring

Marker Target Why
Blood pressure <120/80 mmHg Peptide can raise blood pressure; screens for pressor effect
Full-body skin / mole mapping No new or changing atypical lesions Detects mole darkening, enlargement, or new nevi that could mask or signal melanoma
Resting heart rate 50–70 bpm Screens for cardiovascular strain alongside blood pressure
Renal function (creatinine, eGFR) eGFR >90 mL/min/1.73 m² Screens for the rare renal infarction/rhabdomyolysis risk

Cadence: Skin and blood pressure at baseline; recheck blood pressure at 1–2 weeks after initiation and periodically thereafter; dermatologic skin checks every 6–12 months (sooner if any mole changes).

Qualitative Assessment

  • Appearance, darkening, or enlargement of any mole
  • Energy levels and unusual fatigue
  • Appetite changes and unintended weight loss
  • Any erection lasting beyond a few hours
  • Nausea and flushing severity as a tolerability guide